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Abstract 
 
Alzheimer’s disease (AD) is a complex neurodegenerative disease, affecting millions of people 
worldwide. Whilst a number of studies have focussed on identifying genetic variants that contribute 
to the development and progression of late-onset AD, the majority of these only have a relatively 
small effect size. There are also a number of other risk factors, for example age, gender and other 
co-morbidities, however how these influence disease risk is not known. Therefore, in recent years, 
research has begun to investigate epigenetic mechanisms for a potential role in disease etiology. In 
this chapter, we discuss the current state of play for research into DNA modifications in AD, the most 
well studied being 5-methylcytosine (5-mC). We describe the earlier studies of candidate genes and 
global measures of DNA modifications in human AD samples, in addition to studies in mouse models 
of AD. We focus on recent epigenome-wide association studies (EWAS) in human AD, using 
microarray technology, examining a number of key study design issues pertinent to such studies. 
Finally we discuss how new technological advances could further progress the research field. 
Genetic contributions to Alzheimer’s disease etiology 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that contributes significantly to 
the global disease burden, affecting in excess of 26 million people worldwide (1). Clinically, the first 
signs of AD manifest as a reduction in the ability to retain new information, leading to disruptions in 
daily routine. This is followed by difficulty in planning and solving problems, confusion related to 
time and/or place, speech trouble and mood and personality changes. AD is characterized by the 
accumulation of two proteins that contribute to the neuropathology of the disease: extracellular 
plaques of amyloid-β peptide (Aβ) and neurofibrillary tangles of hyperphosphorylated microtubule 
binding protein tau (2, 3). These neuropathological changes are thought to occur perhaps decades 
before clinical symptoms manifest and the disease is diagnosed (4). Moreover, given that currently 
prescribed medications are simply symptomatic treatments and do not modify the underlying 
disease process, considerable research effort is currently focussed on understanding disease 
etiology.  
 
While the neuropathological manifestation of AD has been well characterized in post-mortem brain 
tissue, less is known about either the underlying risk factors for the disease or the exact mechanisms 
involved in disease progression. Given the high heritability estimates (60–80%) for AD derived from 
quantitative genetic analyses (5), the majority of etiological studies have focussed predominantly on 
genetic contributions to the disease. Indeed autosomal dominant mutations in three genes (APP, 
PSEN1, and PSEN2), which are involved in Aβ production, can explain early onset (<65 years) familial 
AD, however these account for only 5–10% of the total disease burden. Most cases of AD are late-
onset (>65 years), non-Mendelian and highly sporadic, with susceptibility attributed to the action of 
common genetic variants of low penetrance. In recent years a number of genome-wide association 
studies (GWAS), and a subsequent meta-analysis, have nominated around 20 common variants in a 
number of genes including ABCA7, BIN1, CASS4, CD2AP , CELF1, CLU, CR1, FERMT2, FRMD4A, HLA-
DRB5, INPP5D, MEF2C, MS4A4E/MS4A6A, NME8, PICALM, PTK2B, SLC24A4/RIN3, SORL1 and 
ZCWPW1 (6, 7). However collectively these only explain around a third of disease incidence (8), 
although polygenic risk scores based on these variants have been developed to predict disease risk 
(9).  The only common variants identified to date with a modest effect size exist within APOE, where 
the APOE Ɛ4 variant, which arises due to single nucleotide polymorphisms (SNPs) at rs7412 and 
rs429358, is the largest genetic risk factor for late onset AD, with carriers of the Ɛ4Ɛ4 genotype 
having an odds ratio of 14.9 for developing the disease (10). Recent genome sequencing projects 
have identified other variants, for example rs75932628 (R47H) within TREM2 (11, 12), however 
these are relatively rare within the population.  
A role for epigenetics in AD  
 
Although many of the genomic studies to date have identified robust and reproducible findings, they 
do not account for all of AD incidence.  Furthermore, a number of disease attributes suggest a 
potential epigenetic contribution to etiology, for example the differential vulnerability of specific 
brain regions to disease, age of onset of disease, environmental influences on disease such as diet 
and the increased risk of developing AD in individuals with obesity and type II diabetes (13). 
Epigenetic processes mediate the reversible regulation of gene expression, occurring independently 
of DNA sequence variation, acting principally through chemical modifications to DNA and 
nucleosomal histone proteins and orchestrate a diverse range of important neurobiological 
processes. DNA methylation is the best characterized and most stable epigenetic modification 
modulating the transcription of mammalian genomes and has been the focus of most human 
epidemiological epigenetic research to date. Standard genotyping techniques are not able to 
distinguish between unmodified cytosine and 5-methylcytosine (5-mC), which contains a methyl-
group on the 5 position of the cytosine ring. Bisulfite conversion is by far the simplest method to 
assess the degree of DNA methylation present in a given sample as it converts unmethylated 
cytosine to uracil (and to thymine through subsequent PCR), whilst 5-mC is not converted (and thus 
remains as cytosine in PCR). As such, bisulfite-treatment of DNA allows the differentiation between 
cytosine and 5-mC through downstream sequencing, amplification or array-based techniques.   
Epigenetic studies of mouse models of AD 
 
There are many available murine models that have been traditionally used for studying AD. There 
are, however, limitations to their utility for modelling human AD, for example mice do not naturally 
get AD symptoms or produce amyloid plaques. Therefore, in mouse models of amyloid pathology, 
the amyloid is derived from human transgenes and so produces human amyloid.  Currently no 
mouse model has all the features of AD seen in humans, but they have differing combinations of the 
disease characteristics, such as behavioral changes, neurodegeneration, neuropathology and 
cognitive deficits at different ages (14). Although most AD cases are sporadic, transgenic animal 
models have relied on the utilization of genetic mutations associated with familial AD and are thus a 
model of the effects of the accumulation of amyloid-β (Aβ) plaques and/or neurofibrillary tangles, 
rather than a model of sporadic AD, where the causes are unknown. Mouse models have been made 
for mutations in APP (15-17) and knock-out and knock-in mouse models are also available for the 
APP secretases (BACE (18), PSEN1, PSEN2 (19), ADAM10 and ADAM17 (20)). The 3xTg-AD mice, 
which contain human APP, PSEN1, and tau mutant transgenes (21), are useful as they exhibit  both 
plaque and tangle pathology.  Nonetheless, despite this issue of translation from murine models to 
human sporadic patients, there are many advantages to using them to study epigenetic changes 
beyond the advantages common of most mouse models, such as having experimental control and a 
short life span. For example one can assess longitudinal changes in the epigenome across specific 
regions of the brain in genetically identical mice. Furthermore, with specific murine models 
available, which have already been well characterized, one can accurately predict when pathology 
will start to develop and easily look for epigenetic alterations associated with behavioral, cognitive 
and physiological changes at different stages of pathology (14).  
 
To date three epigenome-wide association studies (EWAS) of DNA methylation in AD transgenic mice 
have been published.  The first by Sanchez-Mut et al. analyzed 12 brain regions from C57BL/6J on a 
genome-wide promoter DNA methylation array focussing on 762 genes associated with sensory 
perception, cognition, neuroplasticity, brain physiology and mental disease. They limited their 
investigation to two transgenic mouse models: APP/PSEN1 (double-transgenic mice carrying the 
APPswe/PS1dE9 mutations) and 3xTg-AD, and their analysis of their non-transgenic littermates to 
the prefrontal cortex using only seven genes which had the largest degree of differential methylation 
between cerebral cortex and the rest of the brain. They observed that Tbxa2r, F2rl2, Sorbs3 and 
Spnb4 were hypermethylated in the frontal cortex of APP/PSEN1 and 3xTg-AD mice and were 
replicated in independent samples by pyrosequencing. Further they also found TBXA2R, SORBS3 and 
SPTBN4 to be hypermethylated in AD Braak stage V-VI cases compared to controls (22). 
 
Cong and colleagues performed MeDIP-chip analysis on cortex samples from APP/PSEN1 transgenic 
mice. They identified 2346 hypermethylated CpG sites in 485 unique genes associated with AD 
compared to non-transgenic littermates. Subsequent pathway analyses showed differentially 
methylated genes were enriched in inflammatory response and disease, organismal injury and 
abnormalities, respiratory disease and cancer pathways (23). Another MeDIP-chip study by 
Agbemenyah et al. using hippocampal tissue from APPPS1-21 mice, which have Thy1-APP and Thy1-
PS1 transgenes, found hypomethylation at the Igfbp7 promoter was lower in transgenic mice when 
compared to wild-type. They also demonstrated that Igfbp7 gene expression and IGFBP7 protein 
levels were also increased (24). The majority of DNA methylomic studies of AD, have however 
focussed on studying the human disease in post-mortem brain samples, however there are some 
specific issues when performing EWAS in AD brain samples, which require careful consideration. 
The importance of study design for EWAS in human tissues 
 
Although assessing epigenomic variation is relatively straightforward, there are a number of caveats 
when compared to genomic studies. First, and foremost, epigenomic variation is tissue specific, and 
as such it is important to specifically examine the tissue of interest (25). Given that AD is a 
progressive neurodegenerative disorder, with the spread of neurofibrillary tangles throughout the 
brain being well documented, from the transentorhinal region through the cortex, one would expect 
different regions of the brain to show disease-specific alterations at different stages of the disease 
process. This thus poses the question as to where would be the ideal brain region to profile; areas of 
the brain that are affected early in AD would have large amounts of neuronal loss, whilst other 
regions may not exhibit disease pathology. As such, the profiling of multiple brain regions, 
representing the spectrum of pathology, is optimal as it would allow spatio-temporal mapping of 
disease-related changes. Further by profiling multiple brain regions, one could look for patterns of 
epigenetic changes prior to neuropathology, to attempt to assess causality.  
 
Second is the issue of differences in cell abundance when assessing epigenetic variation in 
heterogeneous tissue such as the brain (26). This is particularly pertinent for diseases such as AD, 
which are characterized by neuronal cell loss and gliosis. Given that distinct cell types have 
potentially different epigenomes, it is important to acknowledge this in analyses. By comparing 
epigenetic changes at a population level in DNA extracted from whole tissue, which is a collection of 
cell types with potentially different methylomes, one will be assessing the percentage of cells which 
do, or do not, have a methylated cytosine at a specific position. This means that cell specific changes 
in heterogeneous cell populations could be diluted by unaffected cell types or could be a 
combination of small changes in many cell types. Some studies have used bioinformatic approaches 
to provide a proxy measure of neuron/glia proportions (27) and include this as a covariate in 
analyses, however the optimal study would use a method such as fluorescence-activated cell sorting 
(FACS) or laser capture microdissection (LCM) to yield pure populations of different cell types prior 
to epigenomic profiling. However, such methods are labor intensive, slow and expensive, and are 
thus not generally feasible for large cohort studies.  Third, sample size is another important 
consideration for EWAS. Although it is generally appreciated that numbers required for EWAS are 
considerably smaller than for a standard GWAS, with ~75 samples per group giving sufficient power 
to detect modest changes (~5%) in DNA methylation. It is however imperative that EWAS are tissue-
specific, and as such it can be challenging to access sufficient numbers of highly characterized brain 
samples from specific brain regions to ensure adequate power. Related to this issue are co-
diagnoses of AD with other dementias. Many post-mortem diagnoses of AD are made in 
combination with other dementias such as Lewy body dementia (LBD) or Vascular dementia (VD). As 
such getting sufficient numbers of donor AD samples for analysis, in the absence of other dementias, 
can be difficult. Although it is of interest to identify molecular mechanisms associated with 
dementia, it is also important to identify disease-specific signatures when looking for new 
pharmacological targets. Finally, many dementia sufferers die with a systemic infection, in fact one 
study of post-mortem records showed that 80% of AD patients had an infection at the time of death 
(28). This could also be a confounder in the analysis of data as infections could elicit the activation of 
pro-inflammatory pathways within the brain. There are thus many issues to consider when planning, 
designing and performing an epigenomic study on any disease, but particularly in age-related 
neurodegenerative diseases such as AD. 
 
 
Aside from identifying novel mechanistic pathways involved in the etiology of AD in the brain, 
epigenomic analyses could allow the development of novel translational clinical tools for AD. 
Although there is growing interest in the identification of novel epigenetic biomarkers for the 
disease in blood, there are other important considerations for these types of studies. A number of 
environmental exposures have been associated with DNA methylation changes in blood cells, for 
example, smoking (29), exposure to environmental chemicals (30) and diet (31), which may not have 
the same effect in disease-relevant tissues and blood may be more susceptible to changes due to the 
environment. Furthermore, the timing of sampling could be important, for example normal aging 
can alter the epigenome (32) and may have differing effects in different tissues. This can be 
somewhat adjusted for with the use of “epigenetic age” tools, which allow one to estimate biological 
age as a result of age sensitive DNA methylation marks, and that can then be used for analysis 
adjustment (32). Using peripheral tissues to find detectable disease-associated differences is a goal 
of most studies due to the fact that neurodegeneration starts decades before clinical diagnosis. To 
date however, no robust epigenetic biomarkers have been identified in blood even though accessing 
larger samples numbers is easier than for brain and relatively non-invasive. The potential of using 
blood or peripheral tissues to develop epigenetic biomarkers is still feasible given the correlation of 
DNA methylation between blood and brain for some, but not all, genetic loci (33). Finally, 
longitudinal studies would be useful in being able to identify epigenetic biomarkers of disease 
progression and neuropathology.  
 
DNA Methylomic studies of human AD 
 
Until relatively recently, published literature examining a role for epigenetic modifications in AD 
development had been largely limited to either speculative reviews, or a limited amount of empirical 
research focussed on candidate genes or global changes. Whilst some global methylomic studies 
using antibodies to detect DNA methylation, have shown reductions in DNA methylation in the 
entorhinal cortex (34), temporal neocortex (35) and hippocampus (36) of AD sufferers post-mortem, 
other studies have reported conflicting results (37-39). A number of candidate gene studies have 
also been carried out in human tissue to try and identify AD associated methylation changes. There 
have been many candidate gene studies on blood on 5-LOX (40), repetitive elements Alu, LINE-1, and 
SAT-α (41, 42), FAAH (43), PIN1 (44), SNAP25 (45), SORL1 and SIRT1 (46) in small numbers of samples 
but some of these were variable in their results.  Other candidate gene studies have used brain 
tissue samples from AD cases and controls to assess DNA methylation. These have used assays for 
HSPA8 and HSPA9 (47), ACE, APOE, APP, BACE1, GSK3B, MAPT, and PSEN1 (48-51), CNP and DPYSL2 
(52), PP2AC (53), RAGE, ADORA2A and UCHL1 (51) with associations with AD being found in APP, 
GSK3B, MAPT, PP2AC , APOE, DNMT1, MTHFR, 5-LOX, FAAH and PIN1. Meanwhile two MethylLight 
PCR studies assessed DNA methylation in AD, the first in 50 candidate genes, and the second 
accessing promoter methylation for a small selection of genes (COX-2, BDNF, NF-κβ, CREB, DBNL, 
SYP, ALOX12 and genes associated with p450 epoxygenase), in a limited number of AD samples (54, 
55). 
 
However, in recent years, advances in epigenomic technology have allowed the quantification of 
DNA methylomic variation in a number of complex disease phenotypes, including AD (Table 1). The 
workhorses for epigenome-wide association studies (EWAS)  have been the Illumina Infinium 27K 
array, the 450K beadarray, and their recent successor, the EPIC 850K array, which are cost-effective 
approaches to screen methylomic variation at ~27,000, ~450,000 and ~850,000 methylation sites in 
the human genome respectively. Other methods, such as methylated DNA immunoprecipitation 
sequencing (MeDIP-seq), whole genome bisulfite sequencing (WGBS) and reduced representation 
bisulfite sequencing (RRBS) are also available, however due to the prohibitive cost of sequencing the 
human genome at sufficient depth, have not been widely utilized in epigenetic epidemiological 
studies of AD. The first empirical EWAS, by Bakulski and colleagues, used the Illumina Infinium 27K 
Beadarray to quantify DNA methylation at ~27,000 CpG sites in the frontal cortex of 12 late-onset AD 
donors and 12 cognitively normal matched control subjects. They identified 948 nominally significant 
DNA methylation differences mapped to 918 unique genes with an average methylation difference 
between AD cases and controls of 2.9%. Interestingly their most significant loci, with a 7.3% 
reduction in AD, resided in the TMEM59 gene, which is believed to be involved in APP post-
translational glycolytic processing (56). Using the same technology Sanchez-Mut and colleagues 
examined hippocampal samples from five control donors to those with early-stage AD (Braak I-II), 
mid-stage AD (Braak III-IV) and late-stage AD (Braak V-VI) (57), demonstrating a >25% methylation 
difference between controls and Braak stage V–VI at single loci in CLDN15 and QSCN6 and two loci in 
DUSP22.  
 
The advent of the Illumina Infinium 450K Beadarray has since allowed more in depth studies of DNA 
methylomic differences in AD. Two independent back-to-back publications both demonstrated 
highly robust and reproducible alterations in four genes not previously associated with AD, namely 
ANK1, RHBDF2, RPL13 and CDH23 (58-60). De Jager et al. used a large cohort of 708 prefrontal 
cortex samples to examine DNA methylomic differences associated with neuritic plaque burden. 
They identified 71 differentially methylated probes, 11 of which were replicated by Lunnon et al. 
Differentially methylated loci associated with neuropathology included genes such as RNF34, CDH23, 
SLC2A1, COQ7 and the HOXA gene cluster and each of the 71 CpGs explained on average 5% of the 
variance in neuritic amyloid plaque burden, with a range of 3.7% to 9.7% (58). In this study, they also 
attempted to look for altered gene expression with AD pathology in the replicated differentially 
methylated genes in independent temporal cortical samples. They  found that 
ANK1, CDH23, DIP2A, RHBDF2, RPL13, SERPINF1 and SERPINF2 all showed differential gene 
expression with amyloid burden providing some evidence of further reaching consequences as a 
result of these DNA methylation differences. 
 
Meanwhile Lunnon and colleagues used a cross-tissue approach to assess DNA methylomic changes 
in AD in a range of brain regions representing the spectrum of AD pathology in a discovery cohort of 
117 individuals (59). They initially focused on the entorhinal cortex, as it shows neuropathology in 
the early stages of disease, to identify a number of differentially methylated loci associated with 
Braak stage, a standardized measure of neurofibrillary tangle deposition. They then examined other 
matched brain regions from the same donors, namely the prefrontal cortex and superior temporal 
gyrus to identify cross-cortex differences in the identified top loci from the entorhinal cortex. Probes 
in ANK1, SLC15A4, MEST and TMX4 were only seen to replicate in the prefrontal cortex, superior 
temporal gyrus or both (59), with probes in PCBD1, MLST8 and ZNF512 not being significant in other 
cortical tissues and probes in SIRT6 and near CLYBL being significant in the cerebellum, a region of 
the brain largely protected from neurodegeneration. They utilized two independent replication 
cohorts to validate their findings, one again utilizing the Illumina Infinium 450K Beadarray to profile 
genome-wide methylomic differences in the prefrontal cortex and superior temporal gyrus in a 
cohort of 147 individuals, and the other utilizing pyrosequencing in the entorhinal cortex, prefrontal 
cortex and superior temporal gyrus of 62 individuals. The authors showed an extended region of 
hypermethylation in the ANK1 gene in AD cortex that spanned at least six CpG sites. 
 
Interestingly ANK1 encodes a brain-expressed protein involved in compartmentalization of the 
neuronal plasma membrane but has not previously implicated in AD. ANK1 is primarily expressed in 
red blood cells but is also expressed in brain and muscle and is thought to play a role in cell-surface 
protein binding to the underlying spectrin-actin cytoskeleton and is used in cell motility, activation, 
proliferation and contact. To date, ANK1 is the most robust AD-associated DNA methylation 
difference observed in the brain (61) (Figure 1). Further studies from the same groups have since 
built on these now publically available EWAS datasets. Chibnik et al. have examined DNA 
methylomic variation in AD loci nominated from GWAS, demonstrating that DNA methylation at 17 
CpG sites spanning six AD-risk genes (BIN1, CLU, ABCA7, MS4A6A, CD2AP and APOE) show an 
association with amyloid burden, independent of genotype, and collectively explain 16.8% of 
variability in neuritic plaques (62). Smith and colleagues examined DNA methylation at a locus within 
the TREM2 gene, showing consistent hypermethylation in three different cohorts in the superior 
temporal gyrus, which appeared to be independent of the SNP previously implicated in the disease 
(63). Finally, Watson et al. used the Illumina Infinium 450K Beadarray to identify AD related DNA 
methylation changes in the superior temporal gyrus in 34 AD cases and 34 matched controls (64). 
They identified 479 differentially methylated regions (DMRs, clusters of significantly differentially 
methylated positions) encompassing 4,565 CpG sites, with the majority of differentially methylated 
positions being hypermethylated. They also showed overlap between their most significant DMRs 
and the Lunnon et al. and De Jager et al. studies, with eight of their top 25 DMRs containing genes 
having differentially methylated positions in the previously published studies 
(LOC100507547, PRDM16, PRRT1, C10orf105, CDH23, PPT2, PPT2-EGFL8 and RNF39) (58, 59). 
 
A role for other DNA modifications in AD? 
 
Although DNA methylation has been the focus of published research to date, a number of additional 
DNA modifications are now starting to receive considerable attention. 5-hydroxymethylcytosine (5-
hmC), 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) were originally thought to represent 
intermediates in the demethylation of 5-mC to un-modified cytosine (65) (Figure 2). However, recent 
evidence suggests that they may represent independent epigenetic marks. There has been particular 
interest in 5-hmC in the context of brain disorders as it appears to be found at relatively high levels 
in the brain compared to other tissues (66, 67) and is particularly enriched in the vicinity of genes 
with synapse-related functions (68). Until recently, studies of 5-hmC in AD brain have been limited to 
global profiling methods, two of which have shown global decreases in the hippocampus (36),  
entorhinal cortex and cerebellum (69), although another study showed increased 5-hmC in the 
middle frontal gyrus and middle temporal gyrus (38), whilst another revealed no difference in the 
entorhinal cortex (37). Given that we know that DNA methylomic differences in AD are loci and 
tissue-specific, and that global studies of alterations in DNA methylation levels were inconclusive, 
this demonstrates the importance of assessing DNA hydroxymethylation levels at single base 
resolution. Interestingly, all of the published EWAS of DNA methylation in AD to date have utilized 
bisulfite converted DNA, however this treatment is unable to convert either 5-mC or 5-hmC to uracil 
(70). As such, all of the published EWAS of AD actually represent a summative measure of these two 
modifications. A recently published adaptation to bisulfite treatment has allowed the simultaneous 
measurement of 5-mC and 5-hmC in a sample. Oxidative bisulfite technology uses a selective 
chemical oxidation to accurately distinguish between 5-mC and 5-hmC by first converting 5-hmC into 
5-fC and through bisulfite conversion this is converted to uracil. As such, this allows the 
quantification of 5-mC in the absence of confounding by 5-hmC. Further, by profiling bisulfite and 
oxidative bisulfite treated DNA in parallel, one can generate a quantitative measurement of 5-hmC 
by subtracting the oxidative bisulfite data from the bisulfite data. This method has been utilized 
together with the Illumina Infinium 450K Beadarray to assess 5-mC and 5-hmC across different 
regions of the human brain (71-73), however there are nuances to the method, for example 
technical artefacts can sometimes result in negative 5-hmC values. Two current studies in AD that 
are expected to be published soon are using this approach to quantify true 5-mC and 5-hmC 
measures in AD brain. Smith et al. have profiled both modifications in the entorhinal cortex and 
cerebellum of 96 individuals ranging from Braak 0 to Braak VI, whilst Roubroeks et al. have assessed 
the middle temporal gyrus in a similar number of individuals.  
Looking to the future 
 
Although the published EWAS in AD have shown a number of robust and reproducible DNA 
modification changes in disease, it is to be expected that technological advances will allow more in 
depth assessments. The recent release of the of Illumina Infinium Methylation EPIC 850K Beadarray 
now allows the simultaneous assessment of ~850,000 methylation sites in the human genome. In 
addition, the falling cost of next generation sequencing means that methods such as RRBS and 
WGBS are becoming more affordable for cohort studies. Similarly the advent of third generation 
sequencing technologies such as the PacBio RS II from Pacific Biosciences allows for whole genome 
sequencing and targeted sequencing. These methods have the potential to detect different DNA 
modifications during standard sequencing as well as allowing for single-base and DNA-strand 
resolution.  Targeted and whole genome sequencing approaches could also be utilized to assess 
epigenetic variation in mitochondrial DNA (mtDNA). Mitochondrial dysfunction has been proposed 
to be a potential mechanism in the development of AD, which has been reported in various studies 
(74, 75). Interestingly, mitochondria possess their own circular genome of 16.6Kb, which is separate 
from the nuclear genome, and contains 37 genes (76). However, with no coverage of the 
mitochondrial genome on the Illumina Infinium Beadarrays, a potential role for mtDNA 
modifications has not been examined in the AD EWAS published to date (77, 78). 
 
 
By far the major criticism of epigenetic studies in various diseases relates to the issue of causality. 
Unlike genetic variation, it is not known whether disease-associated epigenetic changes represent a 
cause or a consequence of disease. Methods such as Mendelian randomisation (MR) with existing 
“omics” datasets could provide some evidence for the direction of effect of the epigenetic changes 
observed but, more recently, there have been suggestions of using genetic editing techniques to 
determine causality. New technologies such as Clustered regularly interspaced short palindromic 
repeats (Crispr)/Cas9 allow researchers to impose genetic modifications to DNA and observe the 
results in cell lines and model organisms (79). This technology could be lent to loci-specific 
epigenetic editing via the use of targeting proteins to methylate of demethylate target sites, and 
then testing whether this accelerates or reverses disease pathology. Previously, CRISPR technology 
has been used to target nuclease activity to introduce single or double strand breaks in DNA, target 
transcriptional transactivation and regulate gene expression. Genome editing with CRISPR targets 
enzyme activity to specific target DNA sequences depending on the specificity of guide RNAs in the 
CRISPR complex. These methods could be used to alter DNA methylation levels in model organisms 
or cell lines to replicate the differences seen in human EWAS studies to attempt to establish 
causality and the effects of disease associated changes. Ultimately, even if such studies prove that a 
nominated locus is not causal in disease, it does not make EWAS any less worthwhile, as even 
identifying consequences of disease will teach us more about the disease process. 
Conclusion 
 
The role of epigenetic mechanisms in AD is still a research field in its infancy, and particularly how 
epigenetic DNA modifications could contribute to the cause and progression of disease is still yet to 
be explored. Currently epigenetics has not been well studied in regards to AD and there are only a 
handful of studies which provide any empirical data. Due to the relative ease and affordability of 
EWAS however, the amount of data being generated is increasing for both 5-mC and 5-hmC. 
Replication is integral to finding robust epigenetic changes and so far, a few replicable differences 
have been observed in relevant brain tissues, such as in ANK1 and genes in the HOXA gene cluster. 
More work is needed and combining multiple EWAS datasets into meta-analyses to provide strong 
evidence for the contribution of DNA methylation to disease progression is warranted. Although 
EWAS using bisulfite treated DNA are a combination of measures of both 5-mC and 5-hmC, using 
oxidative bisulfite methods give a truer measure of 5-mC as well as allowing the quantification of 5-
hmC. As of now, there are no AD epigenetic peripheral tissue biomarkers for AD, which is a major 
goal for dementia research. As epigenetic mechanisms are malleable and changeable over the 
course of development, life, exposure to environmental influences and normal aging, it provides an 
attractive target for a proxy of disease progression and a target for drugs. By combining epigenetic 
measurements in peripheral tissues, such as blood, with neuroimaging and clinical assessments, we 
can associate what is happening in the brain to blood. As with many diseases that are believed to 
have both genetic and environmental components it is important to integrate different data 
modalities to generate a full picture of AD risk. Integrating genomic, epigenomic and transcriptomic 
data will allow the identification of methylation and expression quantitative trait loci 
(mQTLs/eQTLs), showing how genetic variation may influence methylation and expression in a tissue 
and disease-specific manner.  
  
References 
 
1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global 
burden of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's 
Association. 2007;3(3):186-91. 
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and 
problems on the road to therapeutics. Science. 2002;297(5580):353-6. 
3. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. 
Science. 1992;256(5054):184-5. 
4. Mortimer JA, Borenstein AR, Gosche KM, Snowdon DA. Very early detection of 
Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J 
Geriatr Psychiatry Neurol. 2005;18(4):218-23. 
5. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role 
of genes and environments for explaining Alzheimer disease. Archives of general psychiatry. 
2006;63(2):168-74. 
6. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-
wide association study identifies variants at CLU and CR1 associated with Alzheimer's 
disease. Nat Genet. 2009;41(10):1094-9. 
7. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. 
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's 
disease. Nat Genet. 2013;45(12):1452-8. 
8. Ridge PG, Mukherjee S, Crane PK, Kauwe JS, Alzheimer's Disease Genetics C. 
Alzheimer's disease: analyzing the missing heritability. PloS one. 2013;8(11):e79771. 
9. Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. 
Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain : a 
journal of neurology. 2015;138(Pt 12):3673-84. 
10. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects 
of age, sex, and ethnicity on the association between apolipoprotein E genotype and 
Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis 
Consortium. JAMA. 1997;278(16):1349-56. 
11. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. 
Variant of TREM2 associated with the risk of Alzheimer's disease. The New England journal 
of medicine. 2013;368(2):107-16. 
12. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. 
TREM2 variants in Alzheimer's disease. The New England journal of medicine. 
2013;368(2):117-27. 
13. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease 
risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505-12. 
14. Hall AM, Roberson ED. Mouse models of Alzheimer's disease. Brain Res Bull. 
2012;88(1):3-12. 
15. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. 
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid 
precursor protein. Nature. 1995;373(6514):523-7. 
16. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative 
memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 
1996;274(5284):99-102. 
17. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, et 
al. Neuronal overexpression of mutant amyloid precursor protein results in prominent 
deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A. 1999;96(24):14088-93. 
18. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. 
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: 
implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001;10(12):1317-24. 
19. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, 
et al. Loss of presenilin function causes impairments of memory and synaptic plasticity 
followed by age-dependent neurodegeneration. Neuron. 2004;42(1):23-36. 
20. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A 
metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 
1997;385(6618):729-33. 
21. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-
transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and 
synaptic dysfunction. Neuron. 2003;39(3):409-21. 
22. Sanchez-Mut JV, Aso E, Panayotis N, Lott I, Dierssen M, Rabano A, et al. DNA 
methylation map of mouse and human brain identifies target genes in Alzheimer's disease. 
Brain : a journal of neurology. 2013;136(Pt 10):3018-27. 
23. Cong L, Jia J, Qin W, Ren Y, Sun Y. Genome-wide analysis of DNA methylation in 
an APP/PS1 mouse model of Alzheimer's disease. Acta Neurol Belg. 2014;114(3):195-206. 
24. Agbemenyah HY, Agis-Balboa RC, Burkhardt S, Delalle I, Fischer A. Insulin growth 
factor binding protein 7 is a novel target to treat dementia. Neurobiology of disease. 
2014;62:135-43. 
25. Thompson RF, Atzmon G, Gheorghe C, Liang HQ, Lowes C, Greally JM, et al. 
Tissue-specific dysregulation of DNA methylation in aging. Aging cell. 2010;9(4):506-18. 
26. Heijmans BT, Mill J. Commentary: The seven plagues of epigenetic epidemiology. 
International journal of epidemiology. 2012;41(1):74-8. 
27. Guintivano J, Aryee MJ, Kaminsky ZA. A cell epigenotype specific model for the 
correction of brain cellular heterogeneity bias and its application to age, brain region and 
major depression. Epigenetics : official journal of the DNA Methylation Society. 
2013;8(3):290-302. 
28. Burns A, Jacoby R, Luthert P, Levy R. Cause of death in Alzheimer's disease. Age 
and ageing. 1990;19(5):341-4. 
29. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related 
differential DNA methylation: 27K discovery and replication. Am J Hum Genet. 
2011;88(4):450-7. 
30. Ruiz-Hernandez A, Kuo CC, Rentero-Garrido P, Tang WY, Redon J, Ordovas JM, et 
al. Environmental chemicals and DNA methylation in adults: a systematic review of the 
epidemiologic evidence. Clinical epigenetics. 2015;7:55. 
31. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of 
molecular mechanisms and the evidence for folate's role. Adv Nutr. 2012;3(1):21-38. 
32. Horvath S. DNA methylation age of human tissues and cell types. Genome biology. 
2013;14(10):R115. 
33. Hannon E, Lunnon K, Schalkwyk L, Mill J. Interindividual methylomic variation 
across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and 
neuropsychiatric phenotypes. Epigenetics : official journal of the DNA Methylation Society. 
2015;10(11):1024-32. 
34. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic 
changes in Alzheimer's disease: decrements in DNA methylation. Neurobiology of aging. 
2010;31(12):2025-37. 
35. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epigenetic differences in 
cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PloS 
one. 2009;4(8):e6617. 
36. Chouliaras L, Mastroeni D, Delvaux E, Grover A, Kenis G, Hof PR, et al. Consistent 
decrease in global DNA methylation and hydroxymethylation in the hippocampus of 
Alzheimer's disease patients. Neurobiology of aging. 2013;34(9):2091-9. 
37. Lashley T, Gami P, Valizadeh N, Li A, Revesz T, Balazs R. Alterations in global 
DNA methylation and hydroxymethylation are not detected in Alzheimer's disease. 
Neuropathology and applied neurobiology. 2015;41(4):497-506. 
38. Coppieters N, Dieriks BV, Lill C, Faull RL, Curtis MA, Dragunow M. Global 
changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. 
Neurobiol Aging. 2014;35(6):1334-44. 
39. Bradley-Whitman MA, Lovell MA. Epigenetic changes in the progression of 
Alzheimer's disease. Mechanisms of ageing and development. 2013;134(10):486-95. 
40. Di Francesco A, Arosio B, Gussago C, Dainese E, Mari D, D'Addario C, et al. 
Involvement of 5-lipoxygenase in Alzheimer's disease: a role for DNA methylation. Journal 
of Alzheimer's disease : JAD. 2013;37(1):3-8. 
41. Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta F, Cortini F, et al. DNA 
methylation in repetitive elements and Alzheimer disease. Brain Behav Immun. 
2011;25(6):1078-83. 
42. Hernandez HG, Mahecha MF, Mejia A, Arboleda H, Forero DA. Global long 
interspersed nuclear element 1 DNA methylation in a Colombian sample of patients with 
late-onset Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014;29(1):50-3. 
43. D'Addario C, Di Francesco A, Arosio B, Gussago C, Dell'Osso B, Bari M, et al. 
Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PloS one. 
2012;7(6):e39186. 
44. Arosio B, Bulbarelli A, Bastias Candia S, Lonati E, Mastronardi L, Romualdi P, et al. 
Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in 
patients with late-onset Alzheimer's disease. Neurodegener Dis. 2012;10(1-4):207-11. 
45. Furuya TK, Silva PN, Payao SL, Bertolucci PH, Rasmussen LT, De Labio RW, et al. 
Analysis of SNAP25 mRNA expression and promoter DNA methylation in brain areas of 
Alzheimer's Disease patients. Neuroscience. 2012;220:41-6. 
46. Furuya TK, da Silva PN, Payao SL, Rasmussen LT, de Labio RW, Bertolucci PH, et 
al. SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and 
Alzheimer's Disease. Neurochemistry international. 2012;61(7):973-5. 
47. Silva PN, Furuya TK, Braga IL, Rasmussen LT, Labio RW, Bertolucci PH, et al. 
Analysis of HSPA8 and HSPA9 mRNA expression and promoter methylation in the brain 
and blood of Alzheimer's disease patients. Journal of Alzheimer's disease : JAD. 
2014;38(1):165-70. 
48. Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, et al. Altered CpG 
methylation in sporadic Alzheimer's disease is associated with APP and MAPT 
dysregulation. Hum Mol Genet. 2014;23(3):648-56. 
49. Brohede J, Rinde M, Winblad B, Graff C. A DNA methylation study of the amyloid 
precursor protein gene in several brain regions from patients with familial Alzheimer disease. 
J Neurogenet. 2010;24(4):179-81. 
50. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset 
Alzheimer's disease. PloS one. 2008;3(7):e2698. 
51. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related 
genes in postmortem brain. Journal of neuropathology and experimental neurology. 
2009;68(8):880-91. 
52. Silva PN, Furuya TK, Sampaio Braga I, Rasmussen LT, de Labio RW, Bertolucci PH, 
et al. CNP and DPYSL2 mRNA expression and promoter methylation levels in brain of 
Alzheimer's disease patients. Journal of Alzheimer's disease : JAD. 2013;33(2):349-55. 
53. Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, et al. 
Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may 
contribute to Alzheimer disease pathogenesis. Journal of neuropathology and experimental 
neurology. 2004;63(10):1080-91. 
54. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz 
D, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout 
the life span and involves differentiated neurons. PloS one. 2007;2(9):e895. 
55. Rao JS, Keleshian VL, Klein S, Rapoport SI. Epigenetic modifications in frontal 
cortex from Alzheimer's disease and bipolar disorder patients. Translational psychiatry. 
2012;2:e132. 
56. Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman AP, et al. 
Genome-wide DNA methylation differences between late-onset Alzheimer's disease and 
cognitively normal controls in human frontal cortex. Journal of Alzheimer's disease : JAD. 
2012;29(3):571-88. 
57. Sanchez-Mut JV, Aso E, Heyn H, Matsuda T, Bock C, Ferrer I, et al. Promoter 
hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU 
phosphorylation and CREB activation in Alzheimer's disease. Hippocampus. 2014;24(4):363-
8. 
58. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, et al. 
Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 
and other loci. Nature neuroscience. 2014;Sep;17(9):1156-63. 
59. Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, Volta M, et al. 
Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. 
Nature neuroscience. 2014;17(9):1164-70. 
60. Lord J, Cruchaga C. The epigenetic landscape of Alzheimer's disease. Nature 
neuroscience. 2014;17(9):1138-40. 
61. Smith AR, Mill J, Smith RG, Lunnon K. Elucidating novel dysfunctional pathways in 
Alzheimer's disease by integrating loci identified in genetic and epigenetic studies. 
Neuroepigenetics. 2016;6:32–50. 
62. Chibnik LB, Yu L, Eaton ML, Srivastava G, Schneider JA, Kellis M, et al. 
Alzheimer's loci: epigenetic associations and interaction with genetic factors. Ann Clin 
Transl Neurol. 2015;2(6):636-47. 
63. Smith AR, Smith RG, Condliffe D, Hannon E, Schalkwyk L, Mill J, et al. Increased 
DNA methylation near TREM2 is consistently seen in the superior temporal gyrus in 
Alzheimer's disease brain. Neurobiol Aging. 2016;47:35-40. 
64. Watson CT, Roussos P, Garg P, Ho DJ, Azam N, Katsel PL, et al. Genome-wide 
DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures 
associated with Alzheimer's disease. Genome Med. 2016;8(1):5. 
65. Song CX, Yi C, He C. Mapping recently identified nucleotide variants in the genome 
and transcriptome. Nature biotechnology. 2012;30(11):1107-16. 
66. Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, et al. Selective chemical labeling 
reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nature biotechnology. 
2011;29(1):68-72. 
67. Nestor CE, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Dunican D, et al. 
Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. 
Genome research. 2012;22(3):467-77. 
68. Khare T, Pai S, Koncevicius K, Pal M, Kriukiene E, Liutkeviciute Z, et al. 5-hmC in 
the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. 
Nature structural & molecular biology. 2012;19(10):1037-43. 
69. Condliffe D, Wong A, Troakes C, Proitsi P, Patel Y, Chouliaras L, et al. Cross-region 
reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. Neurobiol Aging. 
2014;35(8):1850-4. 
70. Nestor C, Ruzov A, Meehan R, Dunican D. Enzymatic approaches and bisulfite 
sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in 
DNA. BioTechniques. 2010;48(4):317-9. 
71. Stewart SK, Morris TJ, Guilhamon P, Bulstrode H, Bachman M, Balasubramanian S, 
et al. oxBS-450K: a method for analysing hydroxymethylation using 450K BeadChips. 
Methods. 2015;72:9-15. 
72. Lunnon K, Hannon E, Smith RG, Dempster E, Wong C, Burrage J, et al. Variation in 
5-hydroxymethylcytosine across human cortex and cerebellum. Genome biology. 
2016;17:27. 
73. Field SF, Beraldi D, Bachman M, Stewart SK, Beck S, Balasubramanian S. Accurate 
measurement of 5-methylcytosine and 5-hydroxymethylcytosine in human cerebellum DNA 
by oxidative bisulfite on an array (OxBS-array). PloS one. 2015;10(2):e0118202. 
74. Manczak M, Park BS, Jung Y, Reddy PH. Differential expression of oxidative 
phosphorylation genes in patients with Alzheimer's disease: implications for early 
mitochondrial dysfunction and oxidative damage. Neuromolecular medicine. 2004;5(2):147-
62. 
75. Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, Sattlecker M, et al. 
Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease 
blood. Journal of Alzheimer's disease : JAD. 2012;30(3):685-710. 
76. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, et al. 
Sequence and organization of the human mitochondrial genome. Nature. 
1981;290(5806):457-65. 
77. Devall M, Mill J, Lunnon K. The mitochondrial epigenome: a role in Alzheimer's 
disease? Epigenomics. 2014;6(6):665-75. 
78. Devall M, Roubroeks J, Mill J, Weedon M, Lunnon K. Epigenetic regulation of 
mitochondrial function in neurodegenerative disease: New insights from advances in genomic 
technologies. Neuroscience letters. 2016;625:47-55. 
79. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering 
with CRISPR-Cas9. Science. 2014;346(6213):1258096. 
80. Smith RG, Hannon E, De Jager PL, Chibnik L, Lott SJ, Condliffe D, et al. Elevated 
DNA methylation across a 48kb region spanning the HOXA gene cluster on chromosome 7 is 
associated with Alzheimer’s disease neuropathology in the prefrontal cortex and superior 
temporal gyrus. Submitted. 
 
  
Figure 1 – ANK1 shows hypermethylation associated with Braak stage across multiple 
studies. DNA methylation (beta) difference associated with Braak stages at two probes in 
the ANK1 gene (cg11823178 and cg05066959) was observed in the prefrontal cortex (PFC), 
entorhinal cortex (EC) and superior temporal gyrus (STG), but not in the cerebellum in four 
cohorts. London 1 (N=117) and Oxford (N=62) cohort data were taken from Lunnon et al 
(59), MAP/ROS cohort data (N=708) was taken from De Jager et al(58), Mount Sinai cohort 
data was taken from Lunnon et al (59) (N=147). London 2 cohort data (N=94) is currently 
unpublished data from our group. Consistent AD associated hypermethylation was observed 
across all cortical tissues but not in the cerebellum. 
 
 
  
Figure 2 - Epigenetic DNA modifications. DNA methyltransferases (DNMTs) can add and 
maintain methyl groups on cytosine to create 5-methylcytosine (5-mC). Through the action 
of the Ten-Eleven Translocation (TET) family of DNA hydroxylases, the process of active DNA 
demethylation occurs. This occurs via 5-hydroxymethylcytosine (5-hmC), into 5-
formylcytosine (5-fC) and 5-carboxycytosine (5-caC). 
 
 
  
Table 1 – Summary of current EWAS on DNA methylation in AD. A number of studies have examined a role for DNA methylation in Alzheimer’s disease, 
utilising the Illumina Infinium 27K or 450K Beadarrays.  
 
Study Year 
Number of 
Samples 
Tissue(s) Brain bank Method Analysis Genes identified 
Bakulski et al (56) 2012 24 Prefrontal cortex 
Michigan Alzheimer’s 
Disease Center 
27K 
Disease 
Status 
948 CpG sites 
representing 918 genes 
Lunnon et al (59) 2014 117 
Prefrontal cortex  
Superior temporal gyrus 
Entorhinal cortex 
Cerebellum 
Pre-mortem blood 
MRC London 
Neurodegenerative 
Disease Brain Bank  
450K Braak 
ANK1, MIR486, PCBD1, 
SLC15A4, SIRT6, MEST, 
MLST8, ZNF512, TMX4 
De Jager et al (58) 2014 708 Prefrontal cortex 
Religious Order Study 
(ROS) or the Memory 
and Aging Project (MAP) 
450K Amyloid 
ANK1, FOXK1, RHBDF2, 
CDH23, SPG7, RHBDF2, 
KDM2B, WDR81, 
HMHA1, C10orf54, 
ITPRIPL2, PCNT, HOXA3 
Sanchez-Mut et al 
(57) 
2014 20 Hippocampus 
Institute of 
Neuropathology Brain 
Bank 
27K 
Disease 
Status 
DUSP22, CLDN15 and 
QSCN6 
Watson et al (64) 2016 68 Superior temporal gyrus 
Mount Sinai Alzheimer's 
Disease and 
Schizophrenia Brain 
Bank 
450K 
Disease 
Status 
DMRs identified in 475 
genes, enriched for 
neuron function, 
development and 
cellular metabolism. 
Smith et al (80) Submitted 147 
Prefrontal cortex 
Superior temporal gyrus 
Mount Sinai Alzheimer's 
Disease and 
Schizophrenia Brain 
Bank 
450K Braak 
PROM1, ATG16L2, 
CDK14, BTBD11, ETS1, 
HOXA3, ZNF385A 
 
